Belite Bio (FRA:D01) EV-to-OCF: (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D01 Belite Bio Inc FRA:D01
19 GF Score
Price €130.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio EV-to-OCF?

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Belite Bio's Enterprise Value is €5,235.47 Mil. Belite Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €0.00 Mil. Therefore, Belite Bio's EV-to-OCF for today is .

The historical rank and industry rank for Belite Bio's EV-to-OCF or its related term are showing as below:

FRA:D01' s EV-to-OCF Range Over the Past 10 Years
Min: -151.73   Med: 0   Max: -151.73
Current: -151.73

During the past 6 years, the highest EV-to-OCF of Belite Bio was -151.73. The lowest was -151.73. And the median was .

FRA:D01's EV-to-OCF is ranked better than
97.37% of 1408 companies
in the Biotechnology industry
Industry Median: -3.72 vs FRA:D01: -151.73

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-08-31), Belite Bio's stock price is €130.00. Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €-2.348. Therefore, Belite Bio's PE Ratio (TTM) for today is At Loss.


Belite Bio  (FRA:D01) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Belite Bio's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=130.00/-2.348
=At Loss

Belite Bio's share price for today is €130.00.
Belite Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.348.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Belite Bio EV-to-OCF Related Terms


Belite Bio EV-to-OCF Historical Data

* Premium members only.

The historical data trend for Belite Bio's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio EV-to-OCF Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EV-to-OCF
Get a 7-Day Free Trial 0.00 -61.91 -41.77 -63.75 -156.83

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -156.83 0.00 0.00

FRA:D01 vs ORKA, TVTX, COGT: EV-to-OCF Comparison

For the Biotechnology subindustry, Belite Bio's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Belite Bio EV-to-OCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Belite Bio's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where Belite Bio's EV-to-OCF falls into.


FRA:D01
19GF Score
Belite Bio Inc FRA:D01
EV-to-OCF is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio EV-to-OCF Calculation

Belite Bio's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=5235.470/0
=

Belite Bio's current Enterprise Value is €5,235.47 Mil.
Belite Bio's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Belite Bio Business Description

Other Exchanges BLTE:USAD01:Germany
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
19GF Score

Get the complete analysis for FRA:D01

EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€130.00
Price